Public Financing Of Biotechnology: March 2006
I. COMMENCED TRADING IN MARCH | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (M) | Post- Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
| Alexza Pharmaceuticals Inc. (ALXA)1 | 12/22/05 | 3/8/06 | 6.325S | $8 | 23.48 | Piper Jaffray & Co., Pacific Growth Equities (co-lead), RBC Capital Markets, JMP Securities | $50.6 | $187.8 |
OVERALLOTMENT OPTIONS | ||||||||
| Acorda Therapeutics Inc. (ACOR)2 | 10/5/05 | 3/13/06 | 0.576SS | $6 | 19.63 | Banc of America, Lazard Capital Markets, Piper Jaffray & Co., SG Cowen & Co. | $3.5 | $117.8 |
| SGX Pharmaceuticals Inc. (SGXP)3 | 9/2/05 | 3/6/06 | 0.153S | $6 | 14.35 | CIBC World Markets, Piper Jaffray & Co. (co-lead), JMP Securities | $0.92 | $86.1 |
Total: $55.02M | ||||||||
Number of IPOs in March: 1 | ||||||||
Average value of March IPOs: $50.6M | ||||||||
Number of IPOs in 2006: 6 | ||||||||
Total raised in IPOs in 2006: $286.78M | ||||||||
Average value of IPOs in 2006: $47.80M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (M) | Post- Offering Market Cap (M)% |
| Advanced Magnetics Inc. (AMEX:AVM)4 | 12/16/04 | 3/6/06 | 1.233S | $27.46 | 11.29 | ThinkEquity Partners | $33.8 | $310.0 |
| Amylin Pharmaceuticals Inc. (AMLN)5 | 3/27/06 | 3/30/06 | 10S | $46.50 | 121.8 | Morgan Stanley & Co., Lehman Brothers, Goldman, Sachs & Co. (co-lead), Bear, Stearns & Co. | $465 | $5,663.7 |
| BioMarin Pharmaceutical Inc. (BMRN)6 | 3/20/06 | 3/24/06 | 10.35S | $13 | 90.10 | Merrill Lynch & Co., Cowen & Co., Leerink Swann & Co., Pacific Growth Equities, Rodman & Renshaw | $134.6 | $1,171.3 |
| Cepheid Inc. (CPHD)7 | 2/24/06 | 3/8/06 | 10S | $8.60 | 52.76 | UBS Investment Bank, William Blair & Co., Robert W. Baird & Co. | $86.0 | $453.7 |
| Cerus Corp. (CERS)8 | 2/27/06 | 3/16/06 | 5.175S | $8.75 | 27.64 | Robert W. Baird & Co., JMP Securities (co-lead) | $45.3 | $241.8 |
| Dyax Corp. (DYAX)9 | 9/22/05 | 3/9/06 | 5.5S | $5.65 | 43.57 | Deutsche Bank Securities | $31.1 | $246.2 |
| Insmed Inc. (INSM)10 | 3/6/06 | 3/10/06 | 23S | $2 | 89.53 | Lazard Capital Markets, C.E. Unterberg, Towbin (co-lead) | $46.0 | $179.1 |
| Kosan Biosciences Inc. (KOSN)11 | 1/5/05 | 3/30/06 | 5.1S | $5 | 34.47 | Credit Suisse Securities, Cowen & Co. (co-lead) | $25.5 | $172.3 |
Total: $867.30M | ||||||||
Number of follow-on offerings in March: 8 | ||||||||
Average value of March follow-ons: $108.41M | ||||||||
Number of follow-on offerings in 2006: 17 | ||||||||
Total raised in follow-ons in 2006: $1,664.52M | ||||||||
Average value of follow-ons in 2006: $97.91M | ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization is calculated based on the offering price. | ||||||||
1. Alexza raised $50.6M in an IPO of 6.325M shares. Totals include the underwriters' purchase of 825,000 shares per their overallotment option. | ||||||||
2. Underwriters of Acorda's IPO in February exercised their option to purchase 575,614 additional shares. The offering totaled about 6.076M shares and $36.5M in gross proceeds. | ||||||||
3. Underwriters of SGX's IPO in January exercised their option to purchase 152,904 additional shares. The offering totaled about 4.153M shares and $24.9M in gross proceeds. | ||||||||
4. Advanced Magnetics raised about $33.8M in a follow-on offering of 1.233M shares from an existing shelf registration. | ||||||||
5. Amylin raised $465M in a follow-on offering. Underwriters have an option to purchase up to 1.5M additional shares to cover overallotments. | ||||||||
6. BioMarin raised about $134.6M in a follow-on offering. Totals include the underwriters' purchase of 1.35M shares per their overallotment. BioMarin separately sold $172.5M in convertible notes. | ||||||||
7. Cepheid raised $86M in a follow-on offering. Underwriters have an option to purchase up to 1.5M additional shares to cover overallotments. | ||||||||
8. Cerus raised about $45.3M in a follow-on offering from a shelf registration. Totals include the underwriters' purchase of 675,000 shares per their overallotment option. | ||||||||
9. Dyax raised $31.1M in a follow-on offering from a shelf registration. The underwriter has an option to purchase up to 825,000 additional shares to cover overallotments. | ||||||||
10. Insmed raised $46M in a follow-on offering from a shelf registration. Totals include the underwriters' purchase of 3M shares per their overallotment option. | ||||||||
11. Kosan raised $25.5M in a follow-on offering. Totals include the shares purchased by underwriters per their overallotment option. | ||||||||
II. FILED AND PENDING | ||||||||
| Company (Symbol/ Proposed Symbol)#* | Date Filed | Shares/ Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) |
INITIAL OFFERINGS | ||||||
| BioMimetic Therapeutics Inc. (BMTI)1 | 2/10/06 | N/A | N/A | N/A | Deutsche Bank Securities, Pacific Growth Equities (co-lead), First Albany Capital, AG Edwards | $50 |
| BioNumerik Pharmaceuticals Inc. (BNPI)2 | 6/9/04 | 5S | $14-$16 | N/A | UBS Investment Bank, Needham & Co., Leerink Swann & Co., Punk, Ziegel & Co. | $75 |
| Cleveland BioLabs Inc. (CBLI)3 | 2/17/06 | N/A | N/A | N/A | Sunrise Securities | $13.8 |
| Molecular Insight Pharmaceuticals Inc. (MIPI)4 | 11/8/05 | N/A | N/A | N/A | Piper Jaffray & Co., SG Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners | $57.5 |
| Novacea Inc. (NOVC)5 | 2/10/06 | N/A | N/A | N/A | Bear, Stearns & Co., Credit Suisse Securities (co-lead), Pacific Growth Equities, HSBC Securities | $75 |
| Omrix Bio- pharmaceuticals Inc. (OMRI)6 | 1/18/06 | 3.44S | $15-$17 | N/A | UBS Investment Bank, CIBC World Markets (co-lead), Leerink Swann & Co., Oppenheimer & Co. | $55 |
| PTC Therapeutics Inc. (PTCT)7 | 3/31/06 | N/A | N/A | N/A | Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities | $86.25 |
| QuatRx Pharmaceuticals Co. (QTRX)8 | 2/3/06 | N/A | N/A | N/A | Banc of America, Pacific Growth Equities, SG Cowen & Co. (co-lead), Lazard Capital Markets | $86.25 |
| Targacept Inc. (TRGT)9 | 1/17/06 | 5S | $11-$13 | N/A | Deutsche Bank Securities, Pacific Growth Equities (co-lead), CIBC World Markets, Lazard Capital Markets | $60 |
| Vanda Pharmaceuticals Inc. (VNDA)10 | 12/29/05 | 5.8S | $12-$14 | N/A | JP Morgan Securities, Banc of America (co-lead), Thomas Weisel Partners | $75.4 |
WITHDRAWN AND POSTPONED | ||||||
| Company (Symbol/ Proposed Symbol)#* | Date Filed/ Date Pulled | Shares/ Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) |
| Corautus Genetics Inc. (VEGF)11 | 2/24/06/ 3/14/06 | 7.5S | $3.85 | N/A | Lazard Capital Markets, Jefferies & Co. | $28.9 |
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
1. BioMimetic filed to raise up to $50M in an IPO. | ||||||
2. BioNumerik filed to raise up to $86.25M in an IPO. It later proposed selling 5M shares at $14 to $16 per share. The value is based on the midpoint of that price range. | ||||||
3. Cleveland BioLabs filed to raise up to $13.8M in an IPO. | ||||||
4. Molecular Insight filed to raise up to $57.5M in an IPO. | ||||||
5. Novacea filed to raise up to $75.4M in an IPO. | ||||||
6. Omrix filed to raise up to $80.5M in an IPO. It set the price range in March. | ||||||
7. PTC Therapeutics filed to raise up to $86.25M in an IPO. | ||||||
8. QuatRx filed to raise up to $86.25M in an IPO. | ||||||
9. Targacept filed to raise up to $59.8M in an IPO. Terms were set in March. A previous IPO filing was withdrawn in March 2005. | ||||||
10. Vanda filed to raise up to $75M in an IPO. Terms were set in March. | ||||||
11. Corautus terminated an already-priced offering following the release of negative clinical developments the following week. | ||||||